Eli Lilly Stock Climbs on Weight-Loss Drug Trial Results

Shares of pharmaceutical giant Eli Lilly and Co (NYSE:LLY) are on the rise today, up 3.7% at $720.07 at last check. The company's daily weight-loss pill, orforglipron, met its main goal in a late-stage trial, helping type 2 diabetes patients shed 10.5% of their body weight in 72 weeks. This was the last study needed for Eli Lilly to seek approval for the drug globally. On the charts, LLY has been climbing since its August 8th 52-week low of $623.78, heading for its 10th gain in the last 12 sessions. The sha ...